These findings support the combination of PI3Kγ inhibition with PD-L1 immunotherapy against HNSCC and suggest that this approach could improve clinical outcomes for patients with this challenging malignancy. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.